Dai­ichi Sankyo, As­traZeneca say En­her­tu works bet­ter than chemo in cer­tain breast can­cer pa­tients

CHICA­GO — Dai­ichi Sankyo and As­traZeneca’s an­ti­body-drug con­ju­gate En­her­tu gave HER2-low breast can­cer pa­tients a me­di­an of 5 more months with­out can­cer pro­gres­sion or death …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER